Bristol Myers and Cellares Collaborate on Global CAR-T Manufacturing Deal

1. Bristol Myers Squibb (BMS) and Cellares have signed a global collaboration deal to advance the manufacturing of chimeric antigen receptor T-cell (CAR-T) therapies.

2. The partnership aims to diversify manufacturing partners in the biopharmaceutical industry, enabling more efficient and cost-effective production of CAR-T therapies.

3. CAR-T therapies are a type of immunotherapy that involves genetically modifying a patient's T-cells to recognize and attack cancer cells.

4. Cellares is a biotechnology company specializing in cell therapy manufacturing solutions, while BMS is a global biopharmaceutical company with a focus on innovative medicines.

5. The collaboration will leverage Cellares' Cell Shuttle platform, an end-to-end automation solution for cell therapy manufacturing, to streamline the production process.

6. The deal is expected to accelerate the development and commercialization of CAR-T therapies, ultimately benefiting patients with various types of cancer.